HC Wainwright Lowers Invivyd (NASDAQ:IVVD) Price Target to $10.00

Invivyd (NASDAQ:IVVD) had its price target decreased by HC Wainwright from $15.00 to $10.00 in a research report sent to investors on Wednesday,Benzinga reports. HC Wainwright currently has a buy rating on the stock. HC Wainwright also issued estimates for Invivyd’s Q4 2024 earnings at ($0.35) EPS, FY2024 earnings at ($1.63) EPS, Q1 2025 earnings at ($0.02) EPS, Q2 2025 earnings at $0.02 EPS, Q3 2025 earnings at $0.05 EPS, Q4 2025 earnings at $0.08 EPS, FY2025 earnings at $0.15 EPS, FY2026 earnings at ($0.15) EPS, FY2027 earnings at $0.04 EPS and FY2028 earnings at $0.29 EPS.

Separately, EF Hutton Acquisition Co. I upgraded shares of Invivyd to a “strong-buy” rating in a report on Wednesday, October 30th.

Invivyd Stock Performance

Shares of IVVD stock opened at $0.70 on Wednesday. Invivyd has a 12-month low of $0.69 and a 12-month high of $5.20. The firm’s 50 day moving average is $0.97 and its 200 day moving average is $1.24. The stock has a market capitalization of $83.90 million, a P/E ratio of -0.36 and a beta of 0.65.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in IVVD. Vanguard Group Inc. increased its holdings in Invivyd by 3.9% in the 1st quarter. Vanguard Group Inc. now owns 2,611,202 shares of the company’s stock worth $11,594,000 after acquiring an additional 97,496 shares in the last quarter. State Street Corp boosted its position in shares of Invivyd by 3.7% in the third quarter. State Street Corp now owns 1,018,640 shares of the company’s stock worth $1,039,000 after purchasing an additional 35,904 shares during the period. Marshall Wace LLP increased its stake in shares of Invivyd by 4.2% in the second quarter. Marshall Wace LLP now owns 786,899 shares of the company’s stock worth $866,000 after purchasing an additional 31,992 shares in the last quarter. Acadian Asset Management LLC raised its position in shares of Invivyd by 232.0% during the 2nd quarter. Acadian Asset Management LLC now owns 678,706 shares of the company’s stock valued at $745,000 after purchasing an additional 474,301 shares during the period. Finally, Duquesne Family Office LLC purchased a new position in shares of Invivyd during the 2nd quarter valued at $629,000. Institutional investors own 70.36% of the company’s stock.

About Invivyd

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.